Celldex Therapeutics (NASDAQ:CLDX) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02, Zacks reports. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million.

Celldex Therapeutics Trading Down 5.9 %

Shares of Celldex Therapeutics stock traded down $1.22 during trading hours on Monday, reaching $19.35. The stock had a trading volume of 836,327 shares, compared to its average volume of 917,103. The stock's 50 day moving average is $23.75 and its 200 day moving average is $28.80. The firm has a market capitalization of $1.28 billion, a PE ratio of -7.53 and a beta of 1.60. Celldex Therapeutics has a twelve month low of $19.31 and a twelve month high of $53.18.

Analyst Upgrades and Downgrades

Several research firms have commented on CLDX. The Goldman Sachs Group lowered their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday. UBS Group began coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $55.38.

Remove Ads

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.